NKE: Choose Your 'Term'

One of the big brokers is out with positive comments on Nike over the 'near-term.' We're the biggest long-term bulls here of anyone. But unless 'near-term' is six months out, we question this one. Choose your duration wisely here.

 

 

We note the following.

  1. If ‘near-term’  = this quarter, then we’re less optimistic. There still a firm –(300bp) yy gross margin headwind that Nike needs to pass, and then what’s likely to be another meaningful hit in its August quarter.
  2. We absolutely positively agree that Nike’s pricing initiatives will work. But we won’t see it until the November quarter.
  3. Then the February and May quarters of next year are the big margin movers – which, mind you, is also the same time that Nike sells into the Olympics, is coming off of less-stressed inventory levels.
  4. Most importantly, these things will culminate in the sweet spot of execution on its consumer-centric growth platform – which is the key factor that we think takes it from $20bn to $28bn over 3-years. That’s pretty dang solid, longer-term.

 

The bottom line is that estimates for the upcoming quarters have come down to some degree, which is a positive. Perhaps that mitigates the stock getting spanked as the Retail group comes under severe pressure in 2H (per our broader thesis).  But where we come up dry is why this is something that makes the stock go up over the near-term.  For those that love to buy great businesses at great prices, we think you’ll have a better shot at Nike than at $85.


Cartoon of the Day: Crash Test Bear

In the past six months, U.S. stock indices are up between +12% and +18%.

read more

GOLD: A Deep Dive on What’s Next with a Top Commodities Strategist

“If you saved in gold over the past 20 to 25 years rather than any currency anywhere in the world, gold has outperformed all these currencies,” says Stefan Wieler, Vice President of Goldmoney in this edition of Real Conversations.

read more

Exact Sciences Up +24% This Week... What's Next? | $EXAS

We remain long Exact Sciences in the Hedgeye Healthcare Position Monitor.

read more

Inside the Atlanta Fed's Flawed GDP Tracker

"The Atlanta Fed’s GDPNowcast model, while useful at amalgamating investor consensus on one singular GDP estimate for any given quarter, is certainly not the end-all-be-all of forecasting U.S. GDP," writes Hedgeye Senior Macro analyst Darius Dale.

read more

Cartoon of the Day: Acrophobia

"Most people who are making a ton of money right now are focused on growth companies seeing accelerations," Hedgeye CEO Keith McCullough wrote in today's Early Look. "That’s what happens in Quad 1."

read more

People's Bank of China Spins China’s Bad-Loan Data

PBoC Deputy Governor Yi says China's non-performing loan problem has “pretty much stabilized." "Yi is spinning. China’s bad-debt problem remains serious," write Benn Steil and Emma Smith, Council on Foreign Relations.

read more

UnderArmour: 'I Am Much More Bearish Than I Was 3 Hours Ago'

“The consumer has a short memory.” Yes, Plank actually said this," writes Hedgeye Retail analyst Brian McGough. "Last time I heard such arrogance was Ron Johnson."

read more

Buffalo Wild Wings: Complacency & Lack of Leadership (by Howard Penney)

"Buffalo Wild Wings has been plagued by complacency and a continued lack of adequate leadership," writes Hedgeye Restaurants analyst Howard Penney.

read more

Todd Jordan on Las Vegas Sands Earnings

"The quarter actually beat lowered expectations. Overall, the mass segment performed well although base mass lagging is a concern," writes Hedgeye Gaming, Lodging & Leisure analyst Todd Jordan on Las Vegas Sands.

read more

An Update on Defense Spending by Lt. Gen Emo Gardner

"Congress' FY17 omnibus appropriation will fully fund the Pentagon's original budget request plus $15B of its $30B supplemental request," writes Hedgeye Potomac Defense Policy analyst Lt. Gen Emerson "Emo" Gardner USMC Ret.

read more

Got Process? Zero Hedge Sells Fear, Not Truth

Fear sells. Always has. Look no further than Zero Hedge.

read more

REPLAY: Review of $EXAS Earnings Call (A Hedgeye Best Idea Long)

Our Healthcare Team made a monster call to be long EXAS - hear their updated thoughts.

read more